Review: hydroxychloroquine and Chloroquine for treatment of SARS-CoV-2 (COVID-19)

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pastick, Katelyn A.
• dc.contributor.author Okafor, Elizabeth C.
• dc.contributor.author Wang, Fan
• dc.contributor.author Lofgren, Sarah M.
• dc.contributor.author Skipper, Caleb P.
• dc.contributor.author Nicol, Melanie R.
• dc.contributor.author Pullen, Matthew F.
• dc.contributor.author Rajasingham, Radha
• dc.contributor.author McDonald, Emily G.
• dc.contributor.author Lee, Todd C.
• dc.contributor.author Schwartz, Ilan S.
• dc.contributor.author Kelly, Lauren E.
• dc.contributor.author Lother, Sylvain A.
• dc.contributor.author Mitjà, Oriol
• dc.contributor.author Letang Jiménez de Anta, Emilio Ángel
• dc.contributor.author Abassi, Mahsa
• dc.contributor.author Boulware, David R.
• dc.date.accessioned 2020-06-17T06:46:46Z
• dc.date.available 2020-06-17T06:46:46Z
• dc.date.issued 2020
• dc.description.abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, et al. Review: Hydroxychloroquine and Chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 2020 Apr 15; 7(4):ofaa130. DOI: 10.1093/ofid/ofaa130
• dc.identifier.doi http://dx.doi.org/10.1093/ofid/ofaa130
• dc.identifier.issn 2328-8957
• dc.identifier.uri http://hdl.handle.net/10230/44992
• dc.language.iso eng
• dc.publisher Oxford University Press
• dc.relation.ispartof Ppen Forum Infectious Diseases.. 2020 Apr 15; 7(4):ofaa130
• dc.rights Copyright © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword COVID-19
• dc.subject.keyword Hydroxychloroquine
• dc.subject.keyword SARS-CoV-2
• dc.subject.keyword Chloroquine
• dc.subject.keyword Clinical trials
• dc.subject.keyword Coronavirus
• dc.title Review: hydroxychloroquine and Chloroquine for treatment of SARS-CoV-2 (COVID-19)
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion